Background {#Sec1}
==========

Intracranial artery stenosis/occlusion disease (ICASO) is one of the main causes of ischemic stroke \[[@CR1]\]. It is more prevalent in Asians than in Westerners. In Asia, 30--50% of strokes and more than 50% of transient ischemic attacks are caused by ICASO \[[@CR2]\]. Atherosclerosis, chronic injury, infection, cardioembolism, arterial dissection, vasculitis, moyamoya disease (MMD) and rare autoimmune diseases are common cause of ICASO \[[@CR3]\]. The most common cause of ICASO is atherosclerosis, which is commonly caused by acquired factors, such as smoking, hypertension, diabetes mellitus and dyslipidemia \[[@CR3]\]. However, conventional risk factors only explain part of risks and the underlying etiologies is largely unknown. Many studies supported a genetic risk role of ICASO \[[@CR3]--[@CR10]\].

The ring finger protein 213 (*RNF213*) was found to be a susceptibility gene for MMD in East Asian population and the founder rare variant-p.R4810K (rs112735431) was subsequently identified to be associated with non-MMD ICASO which showed stenosis or occlusion of the intracranial major arteries but do not meet the diagnostic criteria of MMD \[[@CR3]--[@CR6], [@CR11]--[@CR21]\]. Meta-analysis showed that *RNF213* p.R4810K increased the risk of ICASO in Chinese (odds ratio, 5.59; 95% confidence interval, 2.12--14.75; *p* = 0.001), but the effect size was significantly lower than that in Japanese and Korean (odds ratios, 10.71 and 28.52; 95% confidence interval, 3.97--28.91; and 11.04--73.67, respectively) \[[@CR22]\]. Further studies found that many non-p.R4810K *RNF213* rare variants have been identified in MMD patients in ethnically diverse populations, including Asians, whites, and Hispanics, while p.R4810K is absent in non-Asian populations, which illustrating allelic genetic heterogeneity of *RNF213* in different ethnic population \[[@CR23]\]. Whether other *RNF213* rare variants contribute to Chinese ICASO is still unknown. Considering the allelic heterogeneity, we performed target exome sequencing of *RNF213* with the aim to identify the rare variants spectrum and their association with ICASO in a Chinese population and further to explore whether the rare variants carriers present specific clinical phenotype or not.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Seven hundred and fifteen ICASO patients were recruited from two university affiliated hospitals (615 from the Second Hospital of Hebei Medical University and 100 from XiangYa Hospital of Central South University) previously \[[@CR9]\]. Among them, only 6 patients carried *RNF213* p.P4810K variants. In order to investigate whether other *RNF213* rare variants associated with ICASO or not, 250 patients were randomly selected from our previous individuals. Allelic frequencies of control individuals were obtained from 1000 Genome Project Chinese Han Population (208 samples, <http://www.internationalgenome.org/home>) and GeneSky in-house database (1007 samples, [http://www.geneskybiotech.com/index.html](http://www.geneskybiotech.com/index.html))). This study was approved by the Medical Ethics Committee of Central South University and all patients signed an informed consent before participating.

Diagnosis of ICASO {#Sec4}
------------------

The ICASO was diagnosed by digital subtraction angiography, computed tomography angiography or magnetic resonance angiography and defined as stenosis or occlusion at terminal and/or proximal portions of the intracranial major arteries without abnormal vascular networks in the basal ganglia that did not meet the diagnostic criteria of MMD. At least 2 physicians(1 radiologist and 1 neurological physician) were required to interpret angiography images results. Demographic information including age, gender, behavioral risk factors (tobacco and alcohol consumption), disease histories of hypertension, diabetes, hyperlipemia were collected by interview or questionnaire. Patients with potential diseases including cardioaortic embolism, coagulopathy, vasculitis, arterial dissection that may leads to cerebral apoplexy were excluded.

FastTarget sequencing {#Sec5}
---------------------

Genomic DNA with high quality suitable for sequencing was extracted from the peripheral blood leukocytes using TIANamp Blood DNA Extraction Kit (TIANGEN BIOTECH CO., LTD, Beijing, China). Protein coding sequences of *RNF213* were selected and a custom panel covering the target regions was designed. Capture target regions contained flanking sequences of 25 bases at the borders of each exon. Target sequencing was performed on Illumina Hiseq/MiSeq high-throughput sequencing platform (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. Raw fastQ files were aligned to the human reference sequence (NCBI Genome build GRCh37, <https://www.ncbi.nlm.nih.gov/genome/guide/human/#download>) with the Burrows-Wheeler Aligner (BWA, <http://bio-bwa.sourceforge.net/>). The HaplotypeCaller from the Genome Analysis Toolkit (GATK, <https://software.broadinstitute.org/gatk/best-practices/>) and VarScan (<http://varscan.sourceforge.net/>) were used for variant calling in the target region. Quality of sequencing was determined with FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) and SIFT (<http://sift.bii.a-star.edu.sg/>) were used for predicting the deleterious level of the functional variants.

Variant filtration {#Sec6}
------------------

After sequencing, a series of filters were used to prioritize variants. Variants were considered higher priority if they were: (a) predicted to affect protein-coding sequences (including nonsynonymous, frameshift deletion, stop-gain variants in exonic or splicing regions); (b) less common in reference databases (Minor allele frequency was less than 0.05 in 1000 Genome project Chinese Han population \[<ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/>\] and GeneSky in-house Database \[<http://www.geneskybiotech.com/>\]); (c) predicted as damaging, possibly damaging or unknown by SIFT or PolyPhen-2; (d) sequencing read depth was higher than 10x.

Statistical analysis {#Sec7}
--------------------

Descriptive analyses were conducted using SPSS 21.0 software (SPSS Inc., Chicago, IL, USA). Continuous variable (age) was presented as the mean ± standard deviation (SD). Categorical variables (hypertension, diabetes, hyperlipemia, smoking, drinking, clinical symptoms and characteristics of stenosis) were presented as proportions. The Weight Sum Statistic (WSS), the Sequence Kernel Association Test (SKAT) and the SKAT-optimal test (SKAT-O) were used to evaluated the statistical significance of variants between affected and control individuals. A continuous weight function proposed by Madsen and Browning was performed to focus on the lower frequency and rarer variants, this weight score method allows both low frequency (MAF \< 0.05) and rare (MAF \< 0.01) variants to contribute to the overall statistic by calculating the logistic weights for each variant and applying them to the analysis according to the following formula \[[@CR24]\]: *w*~*j*~ = 1/\[*MAF*~*j*~(1 − *MAF*~*j*~)\]^1/2^. Student's t-test, Chi-squared test or Fisher's exact test were used to compare the characteristic differences between carriers and non-carriers of *RNF213* rare variants. Threshold of statistical significance was set at *p* value less than 0.05.

Result {#Sec8}
======

Characteristics of participants {#Sec9}
-------------------------------

Of all the 250 patients with ICASO, 77(30.8%) were female and the average age was 57.8 ± 8.6 years (range: 28--70 years). The information of the vascular risk factors, clinical symptoms and characteristics of cerebral artery stenosis were summarized in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of the case participants and controls^d^CharacteristicsICASO(*n* = 250)Age(years) Mean ± SD \[Range\]57.8 ± 8.6 \[28--70\]Female*,* n(%)77(30.8)Risk factors, n(%) Smoking97(38.8) Drinking63(25.2) Hypertension152(60.8) Diabetes60(24.0) Hyperlipemia95(38.0)Clinical symptoms, n(%) Hemorrhage7(2.8) Infarction165(66.0) Ischemia77(30.8) Other9(3.6) Multiple stenosis199(79.6) Location  Anterior circulation^a^36(14.4)  Posterior circulation^b^99(39.6)  Multiple circulation^c^111(44.4)  Others4(1.6)^a^Anterior circulation = *ACA* Anterior cerebral artery, *MCA* Middle cerebral artery, *ICA* Internal carotid artery^b^Posterior circulation = *BA* Basilar artery, *VA* Vertebral artery, *PCA* Posterior cerebral artery^c^Multiple circulation = including both Anterior and posterior circulation^d^Control individuals were obtained from 1000 Genome Project Chinese Han Population and GeneSky in-house database, clinical characteristics were not available

Identification of low frequency and rare variants in target region {#Sec10}
------------------------------------------------------------------

The average value of mean target coverage was 527x, 88.87% of the reads had a Phred-like quality score (Q-score) greater than 30.The proportion of the samples obtained mean coverage \>140x was 94.24%. After variants filtration, 18 variants were found in 39 patients (Table [2](#Tab2){ref-type="table"}). The detail information of these rare variants was shown in Table [3](#Tab3){ref-type="table"}.Table 2Variant Filtration Steps of sequencing and results of gene-based analysisFiltration StepsNumber of variants1.SNVs^a^ located in exonic/ splicing region1882. Nonsynonymous SNVs/ frameshift deletion/ stopgain1253. Variants judged as SIFT prediction = Damaging / unknown and PolyPhen-2 prediction = Possibly damaging/ Probably damaging/ Unknown714. MAF \< 0.05 in 1KGP(Chinese Han population) and GeneSky in-house Database425.Variants with sequenced base depth \> 10x18Result of *RNF213* gene-based analysis MAFP~WSS~P~SKAT~P~SKAT-O~  \< 0.054.88 × 10^−10^9.68 × 10^−6^3.42 × 10^−9^  \< 0.014.56 × 10^−12^2.80 × 10^−6^3.20 × 10^−11a^*SNVs* Single Nucleotide VariantsTable 3Rare variants detected in ICASO patientsPositionGene RegionFunctionVariant^a^SNP IDGenotype^b^SIFT^c^POLYPhen V2^c^cDNAAmino AcidCase1000G_CHBGENESKYChr17:78247076--78,247,076exonicframeshiftc.134delCp.S45 fs--249/1/0208/0/01007/0/0----Chr17:78298891exonicmissensec.3086 T \> Cp.L1029Srs753208141249/1/0208/0/01007/0/0DDChr17:78307986exonicmissensec.4225G \> Tp.D1409Y--249/1/0208/0/01007/0/0DDChr17:78311532splicing--c.4668 + 6C \> T--rs78795452248/2/0205/3/01007/0/0----Chr17:78311620splicing--c.4669-13A \> G--rs750893752249/1/0208/0/0999/8/0----Chr17:78313764exonicmissensec.5597C \> Tp.T1866Irs546687179244/6/0207/1/01007/0/0D--Chr17:78318465splicing--c.6343-13C \> G--rs141121193246/4/0206/2/0992/15/0----Chr17:78319385exonicmissensec.7250 T \> Gp.I2417Srs181965032244/6/0201/7/0992/15/0DPChr17:78326772exonicmissensec.10336C \> Tp.R3446Wrs776943470249/1/0208/0/0992/15/0DDChr17:78350088splicing--c.13186-13 T \> C--rs113236556239/11/0202/6/01006/1/0----Chr17:78353469exonicmissensec.13595 T \> Cp.I4532Trs373648166249/1/0208/0/0975/32/0DDChr17:78354738exonicmissensec.13748G \> Ap.R4583Qrs199887580249/1/0208/0/01007/0/0DDChr17:78355494exonicmissensec.13945C \> Gp.L4649 Vrs61745599249/1/0208/0/01007/0/0DDChr17:78356830exonicmissensec.14030G \> Tp.W4677 Lrs61741961249/1/0208/0/01006/1/0DDChr17:78357541exonicmissensec.14135A \> Tp.N4712I--249/1/0208/0/01007/0/0DDChr17:78360656exonicmissensec.14887C \> Tp.R4963Crs772035323249/1/0208/0/01007/0/0DDChr17:78362497splicing--c.15000 + 8C \> T----249/1/0208/0/01006/1/0----Chr17:78363181splicing--c.15195 + 14C \> T--rs373144473249/1/0208/0/01007/0/0----^a^ Genbank accession number: NM_001256071; ^b^ Genotype presented as wild type/heterozygous/hommozygous^c^ SIFT Score Prediction: D = damaging, T = tolerated; c POLYPHEN Score Prediction: B = benign, P = possibly damaging, D = probably damaging-- Not available

Distribution of rare variants in ICASO patients and gene-based association test {#Sec11}
-------------------------------------------------------------------------------

Eighteen rare *RNF213* variants were found in ICASO including 6 splicing site variants, 11 missenses and 1 frameshift deletion. All the missense variants were predicted to be deleterious, 6 of them were absent from the control individuals, and 6 of them were clustered at the C-terminal domain of *RNF213* (exon 42--68) (Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S1). We identified a total 42 alternative alleles in ICASO patients (*n* = 250) and 117 alternative alleles in controls (*n* = 1215, cumulative allele OR, 1.74; 95%CI, 1.23--2.49, *p* = 0.002). Single-variant association test revealed that none of the SNPs was associated with ICASO (Table [4](#Tab4){ref-type="table"}). Therefore, we focus on gene-based burden test to evaluate the aggregate effects of low MAF variants. We performed WSS, SKAT, SKAT-O test at two MAF thresholds (MAF \< 0.05, 0.01) respectively. The WSS and SKAT-O test using logistic weights to compare *RNF213* functional variants (MAF \< 0.05) showed significantly different allelic distributions between the ICASO patients and control individuals (WSS *p* = 4.88 × 10^− 10^; SKAT *p* = 9.68 × 10^− 6^; SKAT-O *p* = 3.42 × 10^− 9^.). For the rarer *RNF213* functional variants (MAF \< 0.01), gene-based test showed more significant difference (WSS *p* = 4.56 × 10^− 12^; SKAT *p* = 2.80 × 10^− 6^; SKAT-O *p* = 3.20 × 10^− 14^) (Table [2](#Tab2){ref-type="table"}).Table 4Single variant test and cumulative allele odds ratio of *RNF213* rare variantsVariantRefAltCase_RefCase_AltControl_RefControl_AltOR95%CI*p* value^\*^Chr17:78247076--78,247,076C--499124300----0.171Chr17:78298891TC499124300----0.171Chr17:78307986GT499124300----0.171Chr17:78311532CT49822419110.88(0.20--4.00)1.000Chr17:78311620AG499124300----0.171Chr17:78313764CT49462414161.83(0.71--4.71)0.248Chr17:78318465CG49642403270.72(0.25--2.06)0.383Chr17:78319385TG49462408221.33(0.54--3.30)0.716Chr17:78326772CT4991242914.87(0.30--77.95)0.312Chr17:78350088TC489112392381.42(0.72--2.79)0.312Chr17:78353469TC499124300----0.171Chr17:78354738GA499124300----0.171Chr17:78355494CG4991242914.87(0.30--77.95)0.312Chr17:78356830GT499124300----0.171Chr17:78357541AT499124300----0.171Chr17:78360656CT4991242914.87(0.30--77.95)0.312Chr17:78362497CT499124300----0.171Chr17:78363181CT499124300----0.171Total counts89584243,6231171.74(1.23--2.49)0.002^\*^*P* values were calculated using a two-sided Fisher's exact test*Ref* Reference allele(s), *Alt* Alternate allele(s)Case = 250 ICASO patients, Control = 1KG Chinese Han population and GeneSky Database(including 1007 healthy individuals)

Clinical characteristics of patients with and without *RNF213* rare variants {#Sec12}
----------------------------------------------------------------------------

Among the 250 ICASO patients, we found 39 patients carried *RNF213* rare variants and compared the clinical characteristics between the carriers and non-carriers. The results showed that patients with *RNF213* rare variants were older at diagnosis (60.5 ± 6.2 vs 57.3 ± 8.9 years old, *p* = 0.028). Risk factors of ICASO (including smoking, alcohol drinking, hypertension, diabetes, hyperlipemia), clinical symptoms and characteristics of cerebral artery lesions (quantity of lesions, presence of anterior and posterior ICASO) showed no significant difference between two groups (Table [5](#Tab5){ref-type="table"}).Table 5Characteristics of *RNF213* rare variants carriers and non-carriersCharacteristicsCarrier(*n* = 39)Non-carrier(*n* = 211)*p* valueAge(years) Mean ± SD60.5 ± 6.257.3 ± 8.90.028Female, n(%)12(30.8)65(30.8)0.996Risk factors, n(%) Smoking16(41.0)81(38.4)0.756 Drinking14(35.9)49(23.2)0.095 Hypertension29(74.4)123(58.3)0.059 Diabetes12(30.8)48(22.7)0.281 Hyperlipemia14(35.9)81(38.4)0.768Clinical symptoms, n(%) Hemorrhage3(7.7)4(1.9)0.137 Infarction29(74.4)136(64.5)0.23 Ischemia8(20.5)69(32.7)0.13 Other1(2.6)8(3.8)Characteristics of cerebral artery stenosis, n(%) Multiple stenosis29(74.4)170(80.6)0.377 Location  Anterior circulation^a^4(10.3)32(15.2)0.688  Posterior circulation^b^14(35.9)85(40.3)  Multiple circulation^c^20(51.3)91(43.1)  Others1(2.6)3(1.4)^a^Anterior circulation = *ACA* Anterior cerebral artery, *MCA* Middle cerebral artery, *ICA* Internal carotid artery^b^Posterior circulation =*BA* Basilar artery, *VA* Vertebral artery, *PCA* Posterior cerebral artery^c^Multiple circulation = including both Anterior and posterior circulation

Discussion {#Sec13}
==========

In this study, we sequenced the exome of *RNF213* in 250 ICASO patients and identified 18 rare variants in 39 patients. Gene-based association test showed that rare variants of *RNF213* were significantly associated with ICASO. However, there were no significant clinical characteristic differences between the rare variants carriers and non-carriers.

*RNF213* founder mutation-p.R4810K (rs112735431) was identified to be significantly associated with MMD and non-MMD ICASO in East Asia. Other than p.R4810K, numerous rare variants also were identified in MMD cases in previous studies. In Japan, Kamada et al. identified 3 non-p.R4810K rare variants of *RNF213* (p.M3891 V, p.V4567 M and p.V4765 M) among MMD patients \[[@CR11]\]. Subsequently, Moteki et al. found 16 rare coding variants of *RNF213* in MMD cases by exome sequencing, including 2 previously identified variants (p.V4567 M and p.V4765 M) and 14 novel variants (Additional file [1](#MOESM1){ref-type="media"}: Figure S1, Additional file [2](#MOESM2){ref-type="media"}: Table S1) \[[@CR25]\]. In China, researchers identified 40 *RNF213* rare variants among MMD patients. All of these variants were specific in Chinese MMD except p.D4013N (found in Caucasian) and p.R4062Q (found in Caucasian and Japanese) \[[@CR12], [@CR14], [@CR18], [@CR21], [@CR26]\]. Moreover, p.D4863N, p.E4950D and p.A5021V were particularly identified among Chinese MMD patients in several studies \[[@CR12], [@CR14], [@CR21]\]. In non-East Asian countries, numerous *RNF213* variants were identified. Cecci et al. identified 10 variants only in Caucasian MMD patients \[[@CR27]\] and Shoemaker et al. identified 22 variants in multiple non-East Asian population \[[@CR26]\] (Listed in Additional file [2](#MOESM2){ref-type="media"}: Table S1). Whether these rare variants or other *RNF213* rare variants associated with ICASO like p.R4810K or not is unclear currently. In this study, we performed target exome sequencing of *RNF213* in ICASO patients and found 18 rare variants in 39 patients. All the 18 rare variants identified were novel and not have been found in previous MMD studies. This result suggested that *RNF213* rare variants spectrum of Chinese ICASO is distinct from MMD, locus heterogeneity of *RNF213* is highly indicated between ICASO and MMD.

Recent studies suggested that *RNF213* genotypes were associated with MMD phenotypes, numerous studies confirmed that the homozygous p.R4810K variant carriers present earlier onset age, severe symptoms and prognosis \[[@CR13], [@CR17], [@CR28]\]. Zhang et al. demonstrated Chinese MMD patients with *RNF213* p.R4810K were younger at diagnosis than those without *RNF213* rare variants (25 vs 29 years old, *p* = 0.049), more ischemic cases and more likely to occur at posterior cerebral artery \[[@CR21]\]. In addition, researchers also identified the association of *RNF213* variants and ICASO phenotypes. Bang et al. indicated that Korean ICASO patients with *RNF213* p.R4810K variant were younger at diagnosis than those without the variant (52.6 ± 9.6 vs 56.8 ± 12.7 years old, *p* = 0.027) \[[@CR6]\]. But our study showed that mean age at diagnosis of *RNF213* rare variants carriers was older than that of non-carriers. Considering the complicated current medical status of China, it is difficult to confirm the precise onset age during the slow progression of ICASO unless the patients seek a medical treatment at the early stage of ICASO (such as recurrent headache, dizziness and transient ischemic attack). The majority of patients (66.6%) in our study suffered from severe acute cerebral infarction as initial clinical symptoms, so the age at diagnosis in our research may not be able to reflect the true onset age of ICASO.

In our study, the presence of anterior and posterior ICASO showed no significant difference between *RNF213* rare variants carriers and non-carriers. This result is consistent with Bang's study. They reported that the presence of proximal carotid artery and posterior ICASO showed no significant difference between *RNF213* p.R4810K carriers and non-carriers \[[@CR6]\]. But in Shinya's study, all of 10 *RNF213* p.R4810K carriers suffered anterior ICASO and no one suffered posterior ICASO \[[@CR10]\], they defined the posterior circulation as the basilar artery and vertebral artery, patients with posterior cerebral artery stenosis were not found in their case series. The difference of patient selection may explain the discrepancy.

ICASO is caused by environmental and genetic risk factors. Though some specific rare variants of *RNF213* were identified in Chinese ICASO patients, but there were no specific clinical characteristics of the *RNF213* rare variants carriers, which illustrating that rather than *RNF213* variants there may be other risk factors of ICASO in Chinese. Studies focus on multiple factors including genetic and environmental are needed.

The limitation of this study should be mentioned. First, the sample size of our study was relatively small and the strictly matched cerebrovascular disease-free controls were not available; the reference allele frequencies of rare variants in unaffected individuals were obtained from 1000 Genomes Project and Genesky in-house database. Second, atherosclerosis is the most common cause of ICASO, it usually caused by acquired factors, such as hypertension, diabetes mellitus, dyslipidemia, and smoking. However, these information were not available in the control databases, so we cannot take these environmental risk factors as covariate when we implemented the gene-based association test.

Conclusion {#Sec14}
==========

Rare variants of *RNF213* are associated with ICASO in Chinese, but there were no specific clinical characteristics of the *RNF213* rare variants carriers. Genetic diagnosis values for this gene among Chinese ICASO patients are limited. Rather than *RNF213* variants there should be other risk factors of ICASO in Chinese. Studies focus on multiple factors including genetic and environmental are needed.

Additional files
================

 {#Sec15}

Additional file 1:**Figure S1.** *RNF213* variants identified in MMD and ICASO patients around the world. (TIF 712 kb) Additional file 2:**Table S1.** Rare variants of *RNF213* identified in worldwide MMD patients. (XLSX 14 kb)
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